Insomnia, vasomotor symptoms (VMS) and depression often co-occur after the menopause, withconsequent health problems and reductions in quality of life. The aim of this position statement is toprovide evidence-based advice on the management of postmenopausal sleep disorders derived froma systematic review of the literature. The latter yielded results on VMS, insomnia, circadian rhythmdisorders, obstructive sleep apnea (OSA) and restless leg syndrome (RLS). Overall, the studiesshow that menopausal hormone therapy (MHT) improves VMS, insomnia, and mood.Several antidepressants can improve insomnia, either on their own or in association with MHT;these include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptakeinhibitors (SNRIs), and mirtazapine. Long-term benefits for postmenopausal insomnia may also beachieved with non-drug strategies such as cognitive behavioral therapy (CBT) and aerobic exercise.Continuous positive airway pressure (CPAP) and mandibular advancement devices (MADs) bothreduce blood pressure and cortisol levels in postmenopausal women suffering from OSA. However,the data regarding MHT on postmenopausal restless legs syndrome are conflicting.
|Numero di pagine||10|
|Stato di pubblicazione||Published - 2019|